This study was performed to evaluate the pharmacokinetics , bioequivalence , and feasibility of a combined oral formulation of 5-flurouracil ( 5-FU ) and eniluracil ( Glaxo Wellcome Inc. , Research Triangle Park , North Carolina ) , an inactivator of dihydropyrimidine dehydrogenase ( DPD ) .
